(NBIX) Neurocrine Biosciences, Inc. News & Weekly Analysis

Editorial review: Oleksii RyzhkovIndependent educational resourceEditorial standards

US | Healthcare | Biotechnology | NASDAQ

Market cap$14.841B
P/E ratio21.41
Earnings / share6.82
Dividend yield0.00%
Beta0.40
Employees2,500

Company overview

Neurocrine Biosciences, Inc. (NBIX) at a glance

The week in numbers

$1.04B
Consensus quarterly revenue

Zacks reports revenue expected above the year-ago quarter.

Zacks says consensus expects quarterly revenue at this level.

Source report
+26%
Expected EPS change

Consensus forecast describes higher earnings, not realized results.

Zacks attributes this year-over-year change to consensus quarterly EPS.

Source report
-4.23%
Earnings ESP

Reported indicator reflects recently weaker analyst earnings expectations.

Zacks says its most accurate estimate sits below consensus.

Source report
13.1-point improvement
EQ-VAS health change

Clinical patient-reported improvement does not establish commercial performance.

Neurocrine reports the KINECT-PRO mean improvement from baseline.

Source report
Sector
Healthcare
Headquarters
San Diego, California, United States
Chief executive
Kevin C. Gorman
Employees
2,500
Founded
1992
Exchange
NASDAQ
Industry
Biotechnology
Country
US
Trading currency
USD
Official website
neurocrine.com
Company Overview
Read company overview

Neurocrine Biosciences, Inc. is a biopharmaceutical business headquartered in San Diego, California. Founded in 1992, it operates in the Healthcare sector within specialty and generic drug manufacturing. The company has 2,500 employees and is led by Chief Executive Officer Kevin C. Gorman. Its work centers on medicines addressing neurological, psychiatric, endocrine and immunological conditions in domestic and international markets.

The company markets INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease, along with CRENESSITY for congenital adrenal hyperplasia. Its portfolio also includes ALKINDI and Efmody, as well as Orilissa tablets for endometriosis and Oriahnn capsules for uterine fibroids. In 2017, valbenazine, marketed as INGREZZA, gained US approval for treating adults with tardive dyskinesia.

Neurocrine’s clinical programs include candidates for epilepsy, movement disorders, schizophrenia, bipolar mania, Alzheimer’s disease, major depressive disorder, congenital adrenal hyperplasia, and obesity-related metabolic conditions. The company also pursues research in broader neuropsychiatric and neurological indications. Its development activities include licensing and collaboration arrangements with AbbVie, Nxera Pharma UK, Sanofi, Takeda Pharmaceutical, Tanabe Pharma, Voyager Therapeutics and Xenon Pharmaceuticals.

Ownership & major shareholders

Neurocrine Biosciences, Inc. shares trade on NASDAQ under NBIX. A verified breakdown of major shareholders is not included in this profile.

The week in perspective

Weekly briefing

This week’s coverage points to a broader product and pipeline story, led by INGREZZA evidence and rare-disease positioning, but the nearer-term operating read remains the upcoming quarterly report, where consensus expects higher revenue and earnings while estimate signals have weakened.

News balance

3 Positive2 Mixed1 Context

Positive signals

Positive signals include patient-reported INGREZZA outcomes that exceeded a newly defined meaningful-change benchmark in KINECT-PRO, plus expert perspectives positioning VYKAT XR within multidisciplinary Prader-Willi care. Neurocrine also began a mid-stage Alzheimer’s trial; if successful, it could expand its muscarinic CNS opportunity, though efficacy and commercialization remain unproven.

Risks to watch

Risks include a negative earnings-surprise indicator and a small downward consensus EPS revision before results. Commentary also flags potential INGREZZA pricing and reimbursement pressure, alongside VYKAT XR safety, uptake, and regulatory uncertainties. One supplied source is headline-only, and the clinical, publication, and trial updates do not establish sales growth or future approvals.

Developments worth following

Latest news

Zacks

Consensus projects higher quarterly earnings and revenue

Zacks reports consensus expectations for year-over-year increases in Neurocrine’s quarterly earnings and revenue. However, its most recent earnings estimate is below the consensus estimate, producing a negative earnings-surprise indicator and an inconclusive setup for a beat.

If reported results exceed consensus, anticipated revenue and earnings growth could support the commercial narrative. Conversely, the negative surprise indicator and reduced estimate signal uncertainty around whether current expectations will be met.

Read source

Source report

INGREZZA analysis adds patient-reported health benchmark

Neurocrine announced an analysis setting a 6-point EQ-VAS increase as clinically meaningful for tardive dyskinesia patients. In the Phase 4 KINECT-PRO study, reported average health-score improvement exceeded that threshold, alongside previously described quality-of-life and movement improvements.

The analysis may strengthen the clinical value proposition for INGREZZA in payer and clinician discussions if patient-reported benefits influence treatment decisions. It does not report prescription demand, revenue, comparative effectiveness, or reimbursement outcomes.

Read source

The Motley Fool

Headline cites potential portfolio-led long-term growth

The headline and snippet characterize Neurocrine’s drug portfolio as expanding and suggest it could support substantial growth through 2031. No article text was supplied, so the underlying products, assumptions, financial measures, and supporting analysis cannot be assessed.

If portfolio expansion translates into successful launches and sustained adoption, it could diversify Neurocrine’s revenue base. The headline-only evidence provides no basis to assess probabilities, timing, commercial scale, or execution risks.

Read source

Source report

VYKAT XR publication supports rare-disease care positioning

Commentary highlights an expert publication framing VYKAT XR as the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome. It also cites analyst projections and early CRENESSITY launch figures, while identifying future INGREZZA pricing and VYKAT XR execution risks.

Expert support could help establish VYKAT XR’s role in multidisciplinary care if it improves awareness and adoption. Revenue projections and CRENESSITY figures are reported estimates or commentary, not evidence that VYKAT XR sales will achieve modeled outcomes.

Read source

Source report

Phase 2 Alzheimer’s program enters clinical testing

Neurocrine has started a Phase 2 study of oral muscarinic agonist NBI-1117567 for cognitive impairment in adults with mild to moderate Alzheimer’s disease. Commentary says the program broadens the CNS pipeline but remains mid-stage and commercially unvalidated.

Positive Phase 2 evidence could create an additional CNS development option and diversify the pipeline. Failure to demonstrate adequate efficacy or safety, or later development challenges, would limit any contribution to future product breadth.

Read source

Source report

Expert paper frames VYKAT XR within integrated PWS care

Neurocrine announced an expert publication describing hyperphagia in Prader-Willi syndrome as a multidimensional condition requiring integrated care. The experts characterize VYKAT XR as an important pharmacologic advance that can complement behavioral and environmental management.

The publication may support disease education and clarify where VYKAT XR fits in care pathways if clinicians incorporate its framework. It does not provide treatment uptake, comparative data, reimbursement decisions, or realized commercial performance.

Read source

(NBIX) Neurocrine Biosciences, Inc. Bundle

Get Full Bundle:
$17 $9
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5
$9 $5